AAD 2026Abstract 72716
Guselkumab shows better long-term effectiveness and drug survival compared to secukinumab through 84 weeks in patients with moderate-to-severe plaque psoriasis - Results from the German non-interventional G-REAL study
von Kiedrowski R, Gerdes S, Segert MH, Ostendorf R, Groß D, Taut FJH, Scharfenberger L, Jacobsen S, Behrens J, Spindler N, Hoffmann M
AAD Annual Meeting 2026Denver, 27–31 Mar 2026 · published in JAAD 6 Jul 2026
Topics: Psoriasis
Abstract
The abstract’s text is on the JAAD website.
DOI 10.1016/j.jaad.2026.04.960 · Not in PubMed: details from Crossref